<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00053196</url>
  </required_header>
  <id_info>
    <org_study_id>CALGB-100002</org_study_id>
    <secondary_id>U10CA031946</secondary_id>
    <secondary_id>CALGB-100002</secondary_id>
    <secondary_id>CDR0000269301</secondary_id>
    <nct_id>NCT00053196</nct_id>
  </id_info>
  <brief_title>Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer</brief_title>
  <official_title>Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alliance for Clinical Trials in Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Alliance for Clinical Trials in Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving low doses of chemotherapy, such as fludarabine and busulfan, before a donor
      bone marrow or peripheral blood stem cell transplant helps stop the growth of cancer cells.
      It also stops the patient's immune system from rejecting the donor's stem cells. The donated
      stem cells may replace the patient's immune system and help destroy any remaining cancer
      cells (graft-versus-tumor effect). Giving an infusion of the donor's T cells (donor
      lymphocyte infusion) after the transplant may help increase this effect. Sometimes the
      transplanted cells from a donor can also make an immune response against the body's normal
      cells. Giving immunosuppressive therapy after the transplant may stop this from happening.

      PURPOSE: This phase II trial is studying how well donor bone marrow or peripheral stem cell
      transplant works in treating patients with relapsed hematologic cancer after treatment with
      chemotherapy and autologous stem cell transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the feasibility of non-myeloablative allogeneic hematopoietic stem cell
           transplantation by demonstrating that the risk of treatment-related mortality during the
           first 6 months is an acceptable rate of less than 40% in patients with relapsed
           hematologic malignancies after prior high-dose chemotherapy and autologous stem cell
           transplantation.

        -  Determine the response rates (disease-specific partial and complete response) in
           patients treated with this regimen.

        -  Determine the 6-month and 12-month probabilities of response in patients treated with
           this regimen.

        -  Determine the distribution of time-to-progression in patients responding to this
           regimen.

        -  Determine the percent donor chimerism in patients treated with this regimen.

        -  Determine the risk of acute and chronic graft-vs-host disease in patients treated with
           this regimen.

        -  Determine the toxic effects of this regimen in these patients.

        -  Determine the disease-free and overall survival of patients treated with this regimen.

      OUTLINE: This is an open-label study.

        -  Preparative Regimen: Patients receive fludarabine IV over 30 minutes on days -7 to -3
           and busulfan IV over 2 hours every 6 hours (for a total of 8 doses) on days -4 and -3.

        -  Graft vs Host Disease (GVHD) Prophylaxis: Patients who have an HLA-identical donor
           receive oral (or IV if unable to tolerate oral administration) tacrolimus twice daily on
           days -1 to 90 followed by a taper^* until day 150 and methotrexate IV on days 1, 3, and
           6. Patients with a matched related or matched unrelated donor receive oral (or IV if
           unable to tolerate oral administration) tacrolimus twice daily on days -1 to 180
           followed by a taper^* as tolerated; methotrexate IV on days 1, 3, 6, and 11; oral
           mycophenolate mofetil twice daily on days -2 to 60 followed by a taper; and rabbit
           anti-thymocyte globulin IV over 4-6 hours on days -4 to -1 (for a total of 4 doses).

      NOTE: *Tacrolimus may be tapered on days 60-90 if donor chimerism of CD3+ cells is less than
      50% at day 60 or patient has progressive disease

        -  Allogeneic Stem Cell Transplantation: Patients undergo allogeneic bone marrow or
           peripheral blood stem cell transplantation on days 0 and 1. Patients then receive
           filgrastim (G-CSF) subcutaneously daily beginning on day 7 and continuing until blood
           counts recover.

        -  Donor Lymphocyte Infusion (DLI): After day 180 (or day 210 for patients without an
           HLA-identical donor), patients with stable or progressive disease and no active GVHD may
           receive up to 3 DLIs every 8 weeks.

      Patients are followed within 2-3 months, every 3 months for 2 years, and then every 6 months
      for 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2002</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-related mortality</measure>
    <time_frame>6 months post transplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Per cent donor chimerism</measure>
    <time_frame>30, 60, 90, 180 days post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>12 months up to 5 years post study entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft-versus-host disease incidence</measure>
    <time_frame>6 months post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rates</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myeloproliferative Neoplasms</condition>
  <arm_group>
    <arm_group_label>Non myeloblative allogeneic transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non myeloblative allogeneic hematopoietic cell transplantation after prior autologous transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
    <description>2.5mg/kg/day IV infusion over 6 hrs x 4 doses Days -4 to -1 (for MUD and 9/10 related donor transplants only)</description>
    <arm_group_label>Non myeloblative allogeneic transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>5 ug/kg/day subQ injection Day 7 until ANC&gt; 1000/uL for 3 consec days</description>
    <arm_group_label>Non myeloblative allogeneic transplant</arm_group_label>
    <other_name>filgrastim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <description>0.8mg/kg IV infusion over 2 hrs q 6 hrs x 8 doses Days -4 thru -3</description>
    <arm_group_label>Non myeloblative allogeneic transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>30 mg/sq m/day IVBP over 30 min Days -7 thru -3</description>
    <arm_group_label>Non myeloblative allogeneic transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>5 mg/sq m/day IV infusion Days 1, 3, &amp; 6 for HLA-identical donor transplants and Days 1, 3, 6, &amp; 11 for MUD &amp; 9/10 related donor transplants</description>
    <arm_group_label>Non myeloblative allogeneic transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
    <description>15mg/kg PO bid Day -2 to Day 60, then taper as tolerated (for MUD and 9/10 related donor transplants only)</description>
    <arm_group_label>Non myeloblative allogeneic transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
    <description>target serum level is 5-10 ng/mL. Start with 0.03mg/kg PO bid Day -1 to Day 90, then taper thru Day 150 for HLA identical donor transplants and Day -1 to Day 180 then taper for MUD and 9/10 related donor transplants</description>
    <arm_group_label>Non myeloblative allogeneic transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic cell transplantation</intervention_name>
    <description>2,000,000-8,000,000 CD34+ cells total via infusion Days 0 and 1</description>
    <arm_group_label>Non myeloblative allogeneic transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>allopurinol</intervention_name>
    <description>300 mg/day PO Days -8 thru -1</description>
    <arm_group_label>Non myeloblative allogeneic transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed hematologic malignancy, including one of the following:

               -  Chronic lymphocytic leukemia (CLL)

                    -  Absolute lymphocytosis greater than 5,000/mm^3

                    -  Lymphocytes must appear morphologically mature with less than 55%
                       prolymphocytes

                    -  Lymphocyte phenotype with expression of CD19 and CD5

               -  Prolymphocytic leukemia (PLL)

                    -  Morphologically confirmed

                    -  Absolute lymphocytosis greater than 5,000/mm^3

                    -  More than 55% prolymphocytes

               -  Non-Hodgkin's lymphoma or Hodgkin's lymphoma

                    -  Any WHO histologic subtype allowed except mantle cell lymphoma

                    -  Core biopsies allowed if they contain adequate tissue for primary diagnosis
                       and immunophenotyping

                    -  No bone marrow biopsy as the sole diagnostic means for follicular lymphoma

               -  Multiple myeloma

                    -  Active disease requiring treatment

                    -  Durie-Salmon stage I, II, or III

               -  Acute myeloid leukemia

                    -  Documented control (i.e., less than 10% bone marrow blasts and no
                       circulating blasts)

               -  Myelodysplastic syndromes

                    -  Documented disease by WHO criteria

          -  Must have evidence of relapse/progression at least 6 months after prior high-dose
             chemotherapy with autologous hematopoietic stem cell support

          -  Absence of CD23 expression for CLL or PLL allowed provided there is no morphologic
             evidence of mantle cell lymphoma

          -  Availability of any of the following donor types:

               -  HLA-identical sibling (6/6)

               -  9/10 matched related donor by high-resolution molecular typing at HLA A, B, C,
                  DRB1, and DQB1 loci

                    -  Only a single mismatch at one class I or II allele allowed

               -  10/10 matched unrelated donor by high-resolution molecular typing at HLA A, B, C,
                  DRB1, and DQB1 loci

          -  No syngeneic donors

        PATIENT CHARACTERISTICS:

        Age

          -  Under 70

        Performance status

          -  Not specified

        Life expectancy

          -  Not specified

        Hematopoietic

          -  See Disease Characteristics

        Hepatic

          -  Bilirubin no greater than 3 times upper limit of normal (ULN)

          -  AST no greater than 3 times ULN

        Renal

          -  Creatinine clearance at least 40 mL/min

        Cardiovascular

          -  LVEF at least 30% by MUGA

        Pulmonary

          -  DLCO greater than 40%

          -  No symptomatic pulmonary disease

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  HIV negative

          -  No uncontrolled diabetes mellitus

          -  No active serious infection

          -  No known hypersensitivity to E. coli-derived products

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  See Disease Characteristics

        Chemotherapy

          -  See Disease Characteristics

          -  More than 4 weeks since prior chemotherapy

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  More than 4 weeks since prior radiotherapy

        Surgery

          -  More than 4 weeks since prior surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Asad Bashey, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rebecca and John Moores UCSD Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0658</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beebe Medical Center</name>
      <address>
        <city>Lewes</city>
        <state>Delaware</state>
        <zip>19958</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Christiana Care Health Services</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Francis Hospital</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Union Hospital Cancer Center at Union Hospital</name>
      <address>
        <city>Elkton MD</city>
        <state>Maryland</state>
        <zip>21921</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center at Barnes-Jewish Hospital</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey at the Cooper University Hospital - Voorhees</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Comprehensive Cancer Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210-1240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224-1791</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massey Cancer Center at Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298-0037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Bashey A, Owzar K, Johnson JL, Edwards PS, Kelly M, Baxter-Lowe LA, Devine S, Farag S, Hurd D, Ball E, McCarthy P, Lister J, Shea TC, Linker C. Reduced-intensity conditioning allogeneic hematopoietic cell transplantation for patients with hematologic malignancies who relapse following autologous transplantation: a multi-institutional prospective study from the Cancer and Leukemia Group B (CALGB trial 100002). Biol Blood Marrow Transplant. 2011 Apr;17(4):558-65. doi: 10.1016/j.bbmt.2010.07.015. Epub 2010 Jul 30.</citation>
    <PMID>20674758</PMID>
  </results_reference>
  <results_reference>
    <citation>Bashey A, Owzar K, Johnson JL, et al.: Reduced-intensity allogeneic transplantation after failure of autologous transplantation: a prospective multi-center CALGB study. [Abstract] Blood 108 (11): A-3122, 2006.</citation>
  </results_reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2003</study_first_submitted>
  <study_first_submitted_qc>January 27, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2003</study_first_posted>
  <last_update_submitted>June 30, 2016</last_update_submitted>
  <last_update_submitted_qc>June 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>prolymphocytic leukemia</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>atypical chronic myeloid leukemia, BCR-ABL negative</keyword>
  <keyword>myelodysplastic/myeloproliferative neoplasm, unclassifiable</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Allopurinol</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

